Secnidazole

{{Short description|Chemical compound}}

{{cs1 config|name-list-style=vanc}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 464388214

| IUPAC_name = 1-(2-Methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol

| image = Secnidazole.svg

| width = 160

| tradename = Solosec

| Drugs.com = {{drugs.com|international|secnidazole}}

| pregnancy_AU =

| DailyMedID = Secnidazole

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US = Rx-only

| legal_status =

| routes_of_administration = Oral

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 3366-95-8

| ATC_prefix = P01

| ATC_suffix = AB07

| ATC_supplemental =

| PubChem = 71815

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 64839

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = R3459K699K

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D07353

| ChEMBL_Ref = {{ebicite|correct|EBI}}

| ChEMBL = 498847

| ChEBI = 140628

| synonyms = PM-185184; RP-14539; SYM-1219

| chemical_formula =

| C=7 | H=11 | N=3 | O=3

| smiles = [O-] [N+](=O)c1cnc(n1CC(O)C)C

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C7H11N3O3/c1-5(11)4-9-6(2)8-3-7(9)10(12)13/h3,5,11H,4H2,1-2H3

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = KPQZUUQMTUIKBP-UHFFFAOYSA-N

}}

Secnidazole (trade names Flagentyl, Sindose, Secnil, Solosec) is a nitroimidazole anti-infective used to treat bacterial vaginosis and trichomoniasis.{{cite web | title=Evofem Biosciences | website=AdisInsight | date=24 February 2025 | url=https://adisinsight.springer.com/drugs/800040719 | access-date=26 February 2025}}https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209363Orig1s014s016lbl.pdf It is taken orally.

Structurally it actually methyl-metronidazole. Effectiveness in the treatment of dientamoebiasis has been reported.{{cite journal | vauthors = Girginkardeşler N, Coşkun S, Cüneyt Balcioğlu I, Ertan P, Ok UZ | title = Dientamoeba fragilis, a neglected cause of diarrhea, successfully treated with secnidazole | journal = Clinical Microbiology and Infection | volume = 9 | issue = 2 | pages = 110–3 | date = February 2003 | pmid = 12588330 | doi = 10.1046/j.1469-0691.2003.00504.x | doi-access = free }} It has also been tested against Atopobium vaginae.{{cite journal | vauthors = De Backer E, Dubreuil L, Brauman M, Acar J, Vaneechoutte M | title = In vitro activity of secnidazole against Atopobium vaginae, an anaerobic pathogen involved in bacterial vaginosis | journal = Clinical Microbiology and Infection | volume = 16 | issue = 5 | pages = 470–2 | date = May 2010 | pmid = 19548924 | doi = 10.1111/j.1469-0691.2009.02852.x | doi-access = free }}

In the United States, secnidazole is FDA-approved for the treatment of bacterial vaginosis and trichomoniasis in adult women.{{cite journal | vauthors = Muzny CA, Van Gerwen OT | title = Secnidazole for Trichomoniasis in Women and Men | journal = Sex Med Rev | volume = 10 | issue = 2 | pages = 255–262 | date = April 2022 | pmid = 35153156 | doi = 10.1016/j.sxmr.2021.12.004 | s2cid = 246755406 | doi-access = free | pmc = 11019772 }} It was approved in the United States in 2017.